Please Wait
Applying Filters...
menu
    • menu
    Metrochem has been delivering customized volume & quality products to customers across the world, taking utmost care of their needs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    TAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

    Virtual Booth

    Contact Supplier

    Boai NKY Pharmaceuticals Ltd. is one of the largest global PVP suppliers.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-06-09

    Virtual Booth

    An Enquiry

    Menu

    Rebamipide

    ACTIVE PHARMA INGREDIENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PharmaCompass
    $ API Ref.Price (USD/KG) : 131Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 9Mucosta

    02 8Mucosta Ophthalmic Suspension

    03 1Rebamipide Otsuka

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Mucosta Ophthalmic Suspension

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta Ophthalmic Suspension

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 49

    2019 Revenue in Millions : 50

    Growth (%) : -2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Mucosta

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2020 Revenue in Millions : 72

    2019 Revenue in Millions : 82

    Growth (%) : -12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Mucosta

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Disorders

    Currency : USD

    2021 Revenue in Millions : 72

    2020 Revenue in Millions : 69

    Growth (%) : 12

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Mucosta Ophthalmic Suspension

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta Ophthalmic Suspension

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 46

    2020 Revenue in Millions : 47

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Mucosta Ophthalmic Suspension

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta Ophthalmic Suspension

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 42

    2021 Revenue in Millions : 46

    Growth (%) : -9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Mucosta

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2022 Revenue in Millions : 78

    2021 Revenue in Millions : 72

    Growth (%) : 9

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Mucosta Ophthalmic Suspension

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta Ophthalmic Suspension

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2023 Revenue in Millions : 29

    2022 Revenue in Millions : 42

    Growth (%) : -20

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Mucosta

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2023 Revenue in Millions : 71

    2022 Revenue in Millions : 78

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Rebamipide Otsuka

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Rebamipide Otsuka

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2024 Revenue in Millions : 60

    2023 Revenue in Millions : 59

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Mucosta

    Rebamipide

    arrow
    FCE Pharma
    Not Confirmed

    Brand Name : Mucosta

    Japan
    arrow
    FCE Pharma
    Not Confirmed

    Otsuka

    Rebamipide

    Main Therapeutic Indication : Gastrointestinal Diseases

    Currency : USD

    2024 Revenue in Millions : 77

    2023 Revenue in Millions : 71

    Growth (%) : 10

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF